An antibody known as Dupilumab has scored high marks as possible treatment for asthma, according to researchers from the University of Pittsburgh. For the study, the researchers enlisted 108 volunteers around the country to receive a weekly dose of the drug for 12 weeks.
They found that asthma incidents decreased by 86 percent for those taking the antibody as compared to those using a placebo. The drug targets the interleukin-4 (IL-4) receptor specifically, easing symptoms for those suffering from Th-2 type asthma.
"This study targeted those individuals who, on the basis of eosinophil levels in their blood, seemed to have evidence for Th2-type asthma," principal investigator Sally explained. "By using this drug that blocks this pathway, we observed a really robust response compared with placebo in patients with moderate to severe asthma."
For comments and feedback contact: editorial@rttnews.com
Health News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.